We then performed correlation analysis between the six CXCLs family members and tumor immune cells by TIMER in patients with breast cancer (BRCA) and different subtypes (BRCA-Basal, BRCA-Her2, and BRCA-Luminal) to assess the effectiveness of immunotherapy. This evidence concerns the gene ERBB2 and breast cancer.